tbuckley/cabot-search huggingface dataset:
bcr Rearrangement without juxtaposition of c-abl in chronic myelocytic leukemia.
Authors: C R Bartram
Journal: The Journal of Experimental Medicine (1985)

Southern blot analysis detected a bcr gene rearrangement within leukemic cells of a Philadelphia chromosome-negative chronic myelocytic leukemia (CML) patient that led to transcription of a novel 7.3 kb bcr RNA species. Participation of the c-abl oncogene in this genomic recombination could be ruled out by in situ hybridization studies and Northern blot analysis.
Does the emphasis on risk in psychiatry serve the interests of patients or the public? No
Authors: M. Large
Journal: BMJ (2013)

Identifying patients who are likely to harm themselves or others has become central to psychiatry. <b>John Morgan</b> (doi:10.1136/bmj.f902) argues that though the methods are flawed, identifying risk is essential, but <b>Matthew Large</b> thinks we should focus on the wider harms that patients may experience
Encephalitis Due to the Psittacosis-Lymphogranuloma Venereum Group of Viruses
Authors: J. C. Denmark
Journal: BMJ (1957)

MEDICAL MEMORANDA 1i531O Fleming and Miller (1900) reported frank Addison's disease in a mother whose four children were pigmented and subject to attacks of diarrhoea and vomiting.In all these families where post-mortem records are available the essential finding was atrophy of the adrenal cortex in every case.I wish to record my thanks to Dr. P. E. Thompson Hancock, of the Royal Free Hospital, for his help in presenting these cases.
Canadian politicians propose expansion of private health care
Authors: D. Spurgeon
Journal: BMJ (1999)

Canada's publicly funded, universal healthcare plan, which many Canadians consider the pride of their social security system, is currently being challenged by politicians urging more participation of private medicine.

Ralph Klein, the premier of the western province of Alberta, has introduced legislation that will allow private clinics to perform major surgery, such as joint replacement, which under the Canada Health Act is illegal. In addition, Dr Keith Martin, the health spokesman …
Mary L. (Nora) Disis, MD
Authors: Tracy Hampton
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: An observational study
Authors: Lawrence Serfaty, Antoine De Leusse, Olivier Rosmorduc, Benoit Desaint, Jean-Francois Flejou, Olivier Chazouilleres, Renée E. Poupon, Raoul Poupon
Journal: Hepatology (2003)

Ursodeoxycholic acid (UDCA) is the first-line treatment for primary biliary cirrhosis (PBC). The long-term administration of UDCA might indirectly favor colon carcinogenesis by increasing the fecal excretion of secondary bile acids or, in contrast, it might inhibit colon carcinogenesis, as demonstrated in animal models. In patients with PBC, we examined the effect of prolonged UDCA administration on the prevalence and recurrence of colorectal adenoma and on the proliferation of colon epithelial cells. One hundred fourteen patients (103 women, 11 men; mean age, 55 years) with PBC, were enrolled in a colonoscopic surveillance program. The prevalence of colon adenoma was compared in patients already treated with UDCA (mean duration 46 months) at the time of colonoscopy (treated group, n = 52) and in patients undergoing colonoscopy just prior to treatment initiation (untreated group, n = 62). The recurrence of adenoma following removal (mean follow-up, 35 months) was compared between UDCA-treated patients and appropriate age- and gender-matched controls (2/1) selected from a cohort of 205 patients undergoing polypectomy. Epithelial cell proliferation was assessed using anti-Ki67 antibodies on colon biopsies from both treated and untreated patients. Treated and untreated patients displayed similar demographic characteristics. The prevalence of colorectal adenomas was 13% in the treated group versus 24% in the untreated group (P =.16). The colon epithelial cell proliferation index was significantly lower in treated patients than in untreated patients (P =.001). Following removal of the adenoma, the probability of recurrence was significantly lower in patients treated with UDCA than in controls (7% vs. 28% at 3 years, P =.04). In conclusion, this study suggests that, in patients with PBC, the prolonged administration of UDCA (1) is not associated with an increased prevalence of colorectal adenomas, and (2) significantly decreases the probability of colorectal adenoma recurrence following removal. These results are strengthened by the significant reduction in colon epithelial cell proliferation seen in patients treated with UDCA.
Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial
Authors: A. Khemis, A. Kaiafa, C. Queille-Roussel, L. Duteil, J.P. Ortonne
Journal: British Journal of Dermatology (2007)

Melasma is a hyperpigmentation disorder predominantly affecting sun-exposed areas in women, which is often refractory to treatment. Most commercially available treatments incorporate inhibitors of tyrosinase, a key enzyme in melanin production within the melanocyte. In general, however, the efficacy of these therapies is somewhat limited. Recent studies have identified other enzymes that play an important role in melanogenesis, including tyrosinase-related protein-1 (TRP-1), which catalyses the oxidation of the melanogenetic intermediate 5,6-dihydroxyindole-2-carbolylic acid. Rucinol (4-n-butylresorcinol) has been shown to inhibit the activity of both tyrosinase and TRP-1.To assess the efficacy of rucinol serum 0.3% vs. the corresponding vehicle as a treatment for melasma. Secondary objectives were to evaluate local and general tolerability and to assess the skin acceptability of rucinol serum in the target population.In this prospective, single-centre, double-blind, randomized, vehicle-controlled, bilateral (split-face) comparative trial, 32 women with melasma were provided with two identical tubes containing rucinol serum 0.3% or vehicle. The products were each applied to one-half of the face, according to the randomization scheme, twice daily for 12 weeks (phase 1). A broad-spectrum sunscreen (sun protection factor 60) was also applied daily. Assessments at baseline, 4, 8 and 12 weeks included clinical evaluations by a dermatologist, chromametry, ultraviolet and standard photography, and assessments of skin acceptability and tolerability. After 12 weeks, patients were given the option of an additional 3-month treatment period of open full-face rucinol treatment, with reviews at 16, 20 and 24 weeks (phase 2).Twenty-eight patients completed phase 1 and 26 patients completed phase 2. After 12 weeks, the clinical pigmentation score for rucinol-treated skin was significantly lower than for vehicle-treated skin (P = 0.027). During phase 2, rucinol induced a significant reduction in mean pigmentation score on the half of the face previously treated with vehicle. There was also a further, significant improvement on the rucinol-treated side of the face. Chromametry measurements showed that skin was significantly lighter and less yellow, with a strong trend towards reduced redness, following rucinol therapy compared with vehicle. Rucinol serum showed good tolerability and acceptability and was considered to have good or fair efficacy by 78% of the patient population.Rucinol serum was shown to have significant efficacy compared with vehicle alone in improving melasma after 3 months of treatment, according to clinical and objective assessments of skin colour.
Abstract 2615: Amplification and/or high expression of Myc family genes sensitizes tumor cells to aurora kinase inhibitors
Authors: Kenneth E. Hook, Adam Pavlicek, Scott J. Garza, Maruja E. Lira, Keith Ching, Julie Kan, Sreesha P. Srinivasa, James G. Christensen
Journal: Cancer Research (2010)

Abstract The identification of patient populations predicted to derive clinical benefit from systemic treatment regimens is of critical importance for development of targeted therapies. Collective clinical data available for the Aurora kinase inhibitor class of targeted therapies has indicated that broad single agent clinical activity is not readily apparent. We screened a panel of established lung (mostly non-small cell) and colon cell lines for growth inhibitory sensitivity to PF-03814735, an Aurora family kinase inhibitor, revealing a potential correlation with Myc family amplification or expression. The Aurora kinases A and B have been shown to be functionally linked with Myc family oncoproteins in a number of tumor types. Myc family gene amplification events have been reported in about 30% of small cell lung cancer (SCLC) primary tumors and around 50% of cell lines established from SCLC. We next screened a panel of around 20 SCLC lines for sensitivity to PF-03814735 and its relationship to Myc family gene copy number and gene expression levels. Sensitivity to PF-03814735 in vitro was strongly correlated with amplification events in at least one of the Myc family genes (c-Myc, L-Myc, N-Myc) as well as mRNA expression levels of those genes. Myc family expression demonstrated a significant correlation with gene copy number. Follow up studies to evaluate antitumor efficacy in two SCLC xenograft models, H82 (c-Myc) and H69 (N-Myc), indicated significant tumor growth inhibition by PF-03814735. However, the SCLC models were not appreciably more sensitive to PF-03814735 than several non-Myc amplified tumors studied previously (HCT-116, COLO-205, MDA-MB-231) indicating that further study of optimal dose schedule and/or the molecular basis of sensitivity is warranted. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2615.
The evolutionary social psychology of religious beliefs
Authors: Lee A. Kirkpatrick
Journal: Behavioral and Brain Sciences (2004)

Atran &amp; Norenzayan (A&amp;N) are correct that religion is an evolutionary by-product, not an adaptation, but they do not go far enough. Once supernatural beliefs are enabled by processes they describe, numerous social-cognitive mechanisms related to attachment, social exchange, coalitional psychology, status and dominance, and kinship are crucial for explaining the specific forms religion takes and individual and cultural differences therein.
Severe dermatitis and "biological" detergents.
Authors: G A Peterkin
Journal: BMJ (1970)

MEDBITCSJNHALdescribed, probably nine would fall into the category of true primary irritation, but whether any of these are due to detergents or, more particularly, are the same as the cases described by Dr. N. E. Jensen (31 January, p. 299) could only be established by a careful investigation into the aetiology.The manufacturers of detergents are only too conscious of their responsibility to the public
Repeat Administration of Proteins to the Eye With a Single Intraocular Injection of an Adenovirus Vector
Authors: Duncan McVey, Melissa M Hamilton, Chi Hsu, C Richter King, Douglas E Brough, Lisa L Wei
Journal: Molecular Therapy (2008)

Delivery of therapeutic proteins, such as antiangiogenic proteins, to the eye is a demonstrated method for the control of age-related macular degeneration (AMD). However, one of the key limitations is the requirement for frequent and repeated intraocular injections. In this article, we demonstrate that repeated protein production in the eye can be stimulated from the cytomegalovirus (CMV) promoter without repeat intraocular injections using a small molecule, all-trans retinoic acid (ATRA). ATRA by systemic delivery can stimulate protein production multiple times in the eye. Administration of ATRA resulted in stimulation of gene expression to relevant levels that block abnormal blood vessel growth in an experimental animal model for AMD. These data support the principles of this technological discovery to therapeutic applications for chronic ocular diseases.
IMMUNITY OF MICE FOLLOWING SUBCUTANEOUS VACCINATION WITH ST. LOUIS ENCEPHALITIS VIRUS
Authors: Leslie T. Webster
Journal: The Journal of Experimental Medicine (1938)

1. Susceptible mice injected subcutaneously or intraperitoneally with 15,000 intracerebral lethal doses of St. Louis encephalitis virus develop an immunity in 4 to 7 days to 1,000 to 1,000,000 lethal doses given either intracerebrally or intranasally. 2. This immunity persists 4 to 6 weeks, then decreases gradually and disappears after 8 to 12 weeks. 3. More than 1,000 intracerebral doses of virus given as a vaccine do not materially increase the amount or duration of the immunity; less than 1,000 doses give little or no immunity. 4. Test virus injected intracerebrally into immunized mice induces few lesions and is rapidly destroyed; instilled intranasally, it rarely reaches the olfactory lobes or brain. 5. While immunity is maximum, circulating neutralizing antibodies are not detectable. Moreover, the immunity is not affected by endothelial cell blockade or by splenectomy. 6. A few moments after the immunizing virus is given, it can be recovered from the blood in relatively high concentration. After 24 hours, the blood no longer contains demonstrable virus nor do any organs thus far tested except the spleen. The brain and cord remain entirely normal. The spleen, however, becomes enlarged and harbors virus for as long as 30 days.
Medical Service Utilization by Veterans Seeking Help for Posttraumatic Stress Disorder
Authors: Patrick S. Calhoun, Hayden B. Bosworth, Steven C. Grambow, Tara K. Dudley, Jean C. Beckham
Journal: American Journal of Psychiatry (2002)

Posttraumatic stress disorder (PTSD) has been associated with higher rates of health complaints and medical conditions diagnosed by physicians, yet research examining the relationship between PTSD and health care utilization has been limited. This study compared the health service use of veterans with PTSD to that of help-seeking veterans without PTSD. The relationship between severity of PTSD and service utilization was also examined.Data were collected from 996 veterans seeking an evaluation at a Veterans Affairs (VA) Medical Center specialty PTSD clinic in the southeastern United States between March 1992 and September 1998. Data included sociodemographic characteristics, severity of PTSD, and disability status. The outcome variable, VA health service utilization, was prospectively assessed 1 year from the date of the initial PTSD assessment.Although the use of VA mental health services by patients with PTSD was substantial (a median of seven clinic stops), these patients used more services in general physical health clinics that provided predominantly nonmental health services (a median of 18 clinic stops). Negative binomial regression models revealed that younger veterans with PTSD had greater health care utilization than those without PTSD who also sought services. Greater severity of PTSD was related to higher rates of mental and physical health service use among veterans without a service-connected disability.PTSD is associated with substantial health service use. The results highlight the importance of increased collaboration between primary care and mental health specialists, given that patients with PTSD are more likely to receive treatment in nonmental health clinics.
Ampicillin and urticaria.
Authors: E. T. Knudsen
Journal: BMJ (1969)

MEDIISOURshowed crystal clear fluid under normal pressure.Microscopic examination showed no cells, and the protein content was 35 mg./100 ml.It was thought that the hypertensive crisis might be a consequence of the drug therapy.In case the administration of pethidine was a contributory factor, she was treated with a forced acid diuresis and a minimal urine pH of 4-8 was obtained.The blood pressure started to fall and by 10 hours after the ingestion of Mucron it had reached a level of 130/70.The blood pressure remained normal during the rest of her stay in hospital, and on follow-up one month later she was normotensive and asympto- matic apart from a mild depression.a limited number of patients with this type of rash investigated so far we have been unable to demonstrate circulating reaginic antibodies in the serum.It is now well established that
Empirical and rational approaches for development of inhibitors of the human immunodeficiency virus — HIV-1
Authors: W. Prusoff, T.-S. Lin, A. Pivazyan, A.S. Sun, E. Birks
Journal: Pharmacology & Therapeutics (1993)

The human immunodeficiency virus, HIV-1, is generally accepted to be responsible for AIDS. It is imperative that all approaches, empirical and rational, be taken for development of a drug for therapy of this disease. These approaches are discussed, with emphasis on the direction being pursued in our laboratory. Empirically, we found 3'-deoxy-2',3'-didehydrothymidine, a compound first synthesized for potential anticancer activity by J. Horwitz in the 1960s, to be a potent inhibitor of HIV-1. It is now in Phase II/III clinical trials. We have also synthesized several 2,5'-anhydro pyrimidine nucleoside analogs, which have interesting chemical and biological properties. We have evaluated a natural product, gossypol and synthesized various derivatives for anti-HIV-1 activity, but none were appreciably more inhibitory than the parent compound. More recently, we have taken the rational approach and synthesized a boron-modified tetrapeptide, Ac-Thr-Leu-Asn-boro-Phe, which corresponds to the COOH-terminal of the Phe-Pro scissle bond of the gag/pol gene polyprotein product. Potent inhibition of the HIV-1 encoded protease was observed. These approaches and findings will be discussed.
Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early-Stage Non-small Cell Lung Cancer
Authors: Ana Belén Custodio, José Luis González-Larriba, Jana Bobokova, Antonio Calles, Rafael Álvarez, Eugenio Cuadrado, Aranzazu Manzano, Eduardo Díaz-Rubio
Journal: Journal of Thoracic Oncology (2009)
Managing Endocrine and Metabolic Problems in the Patient With Advanced Cancer
Authors: Albert Segaloff
Journal: JAMA (1981)

EVEN though the emergency room is jammed with patients with nausea and vomiting, and the telephone is constantly ringing and bringing similar complaints, if a patient has cancer, hypercalcemia may be present. A patient may indeed have the epidemic infection, but symptomatic hypercalcemia can be induced or exacerbated by such an "infection." The most common metabolic consequence of being host to a malignant disease is hypercalcemia, which is potentially lethal. Breast cancer patients manifest hypercalcemia most frequently because breast cancer itself is one of the most common cancers and because it has the highest percentage of patients who experience symptomatic hypercalcemia at some time during the course of their illness. It is characterized by a normal or elevated level of serum phosphorus along with an elevated calcium level. The serum parathyroid hormone (PTH) level, as measured by radioimmunoassay, is generally within normal limits. If a patient with metastatic breast cancer
Sudden Infant Death Syndrome
Authors: Leslie, L. Barton
Journal: JAMA (1970)

The sudden infant death syndrome (SIDS) claims one out of every 350 infants as its victim. Death comes unexpectedly and inexplicably while the infant sleeps in his crib. Microepidemics of SIDS occur, attacking by preference the infants of poorer families in crowded urban dwellings. The investigation of this syndrome gained impetus from the First International Conference on SIDS held in 1963. "The purpose of the 1969 conference was to subject the work performed in the past five years to critical review, and again to recommend future research priorities." The substance of this latter meeting has now been published by the University of Washington Press.<i>Sudden Infant Death Syndrome</i>contains sections on terminology, epidemiology, pathology, virology, and physiology. The appendix describes the role of lay groups in supporting the victims' parents, educating the public, and stimulating research. An extensive list of references is provided. The book, despite the claims of editors
Bronchocentric granulomatosis and central diabetes insipidus successfully treated with corticosteroids
Authors: GP Rossi, E Pavan, M Chiesura-Corona, F Rea, A Poletti, AC Pessina
Journal: European Respiratory Journal (1994)

Bronchocentric granulomatosis (BCG) is a rare chronic granulomatous lung disease that leads to destruction of the airway walls. It has been observed in association with various conditions, but never, so far, been reported to involve the central nervous system. We report a case of histologically confirmed pulmonary bronchocentric granulomatosis temporally associated with a partial central diabetes insipidus (CDI). Although the pathological basis of the posterior pituitary gland involvement was not ascertained, the temporal association of bronchocentric granulomatosis and central diabetes insipidus, as well as the fact that corticosteroid treatment provided stable remission of both conditions after a 10 month follow-up, strongly suggest that central diabetes insipidus was aetiologically related to bronchocentric granulomatosis in this patient.